Mazen Hanna
Präsident bei Transgenex Nanobiotech, Inc.
Profil
Mazen Hanna is the founder of Nektar Therapeutics UK Ltd., Thar Pharmaceuticals, Inc. He is currently the President & Director at Transgenex Nanobiotech, Inc. His former position was Director & Chief Scientific Officer at Thar Pharma Ltd.
He holds a doctorate degree from the University of Bradford and an undergraduate degree from the University of Baghdad.
Aktive Positionen von Mazen Hanna
| Unternehmen | Position | Beginn |
|---|---|---|
Transgenex Nanobiotech, Inc.
 Transgenex Nanobiotech, Inc. BiotechnologyHealth Technology Transgenex Nanobiotech, Inc. operates as a biotechnology company which engages in the discovery and development of nanoparticle formulations and nano-encapsulation methods for the treatment of acute and chronic lung diseases and cancers. It focuses on the development and marketing of diagnostic reagents/kits for the early detection of cancers and viral infections. The company was founded by Subhra Mohapatra and Shyam Mohaptra in 2004 and is headquartered in Lutz, FL. | Präsident | - |
Ehemalige bekannte Positionen von Mazen Hanna
| Unternehmen | Position | Ende |
|---|---|---|
Thar Pharmaceuticals, Inc.
 Thar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thar Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. The firm focuses on transforming intravenous drugs into oral drugs for existing and new indications. The company was founded by Mazen Hanna and Raymond K. Houck and is headquartered in Pittsburgh, PA. | Gründer | 01.11.2016 |
| Thar Pharma Ltd. | Technik-/Wissenschafts-/F&E-Leiter | - |
Nektar Therapeutics UK Ltd.
 Nektar Therapeutics UK Ltd. Pharmaceuticals: MajorHealth Technology Part of Nektar Therapeutics, Nektar Therapeutics UK Ltd. develops and manages the exploitation of patented technology for controlled particle formation. The company is based in Bradford, UK. Nektar Therapeutics was acquired by Nektar Therapeutics on January 09, 2001 for $140.98 million. The British company was founded by Mazen Hanna, Gwynfor Owen Humphreys. | Gründer | - |
Ausbildung von Mazen Hanna
| University of Bradford | Doctorate Degree |
| University of Baghdad | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 4 |
|---|---|
Thar Pharmaceuticals, Inc.
Thar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thar Pharmaceuticals, Inc. operates as a specialty pharmaceutical company. The firm focuses on transforming intravenous drugs into oral drugs for existing and new indications. The company was founded by Mazen Hanna and Raymond K. Houck and is headquartered in Pittsburgh, PA. | Health Technology |
Nektar Therapeutics UK Ltd.
Nektar Therapeutics UK Ltd. Pharmaceuticals: MajorHealth Technology Part of Nektar Therapeutics, Nektar Therapeutics UK Ltd. develops and manages the exploitation of patented technology for controlled particle formation. The company is based in Bradford, UK. Nektar Therapeutics was acquired by Nektar Therapeutics on January 09, 2001 for $140.98 million. The British company was founded by Mazen Hanna, Gwynfor Owen Humphreys. | Health Technology |
| Thar Pharma Ltd. | |
Transgenex Nanobiotech, Inc.
Transgenex Nanobiotech, Inc. BiotechnologyHealth Technology Transgenex Nanobiotech, Inc. operates as a biotechnology company which engages in the discovery and development of nanoparticle formulations and nano-encapsulation methods for the treatment of acute and chronic lung diseases and cancers. It focuses on the development and marketing of diagnostic reagents/kits for the early detection of cancers and viral infections. The company was founded by Subhra Mohapatra and Shyam Mohaptra in 2004 and is headquartered in Lutz, FL. | Health Technology |
